Granules India inches up on launching two advanced Centres of Excellence at IIT Hyderabad
Granules India is currently trading at Rs. 569.35, up by 0.65 points or 0.11% from its previous closing of Rs. 568.70 on the BSE.
The scrip opened at Rs. 568.30 and has touched a high and low of Rs. 571.85 and Rs. 565.10 respectively. So far 15973 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 627.45 on 03-Dec-2024 and a 52 week low of Rs. 412.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 571.85 and Rs. 543.00 respectively. The current market cap of the company is Rs. 13783.58 crore.
The promoters holding in the company stood at 38.82%, while Institutions and Non-Institutions held 32.01% and 29.17% respectively.
Granules India has launched two advanced Centres of Excellence at the Technology Research Park of IIT Hyderabad: the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering. Ascelis Center of Excellence for Peptide Development and Characterization has been established under Ascelis Peptides, the CDMO arm of the company. This center will drive the development of cosmetic, therapeutic, and pharmaceutical peptides. It is Ascelis’ first development and characterization facility in India and is equipped for primary, secondary, and tertiary structure characterization. The center brings advanced analytical and process development capabilities in-house and will work in collaboration with the company’s Swiss-based R&D facility Senn Chemicals, strengthening the group’s integrated global peptide offering and reducing reliance on external partners.
The Granules Center of Excellence for Particle Engineering will advance polymorph research, material science, and novel drug delivery systems, including amorphous solid dispersions. It replaces earlier external and ad-hoc development with a dedicated research platform that enables first-to-file opportunities, enhances formulation performance, and supports the creation of proprietary technologies for regulated markets.
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
